ClinicalTrials.gg
TerminatedNCT00079911Updated Nov 24, 2020

A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons

A Phase 4 interventional study of valacyclovir hydrochloride in Herpes Genitalis, sponsored by GlaxoSmithKline. Terminated at 5 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-24.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Why this study was terminated
Terminated

From the registry’s dates

  • Primary completion was Oct 2004, 22 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
7
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing valacyclovir in Herpes Genitalis — none open to participants now, none under way, none of them phase 3. Valacyclovir · Herpes Genitalis.

Enrollment
11th of 11
7 · median 50
Started
2004
with 2 others
Phase 4
6 of 14
none open now
Registered
5th of 14
by date
Lead sponsor
4 of 14
GlaxoSmithKline

Among the 14 studies testing valacyclovir in Herpes Genitalis, this one is the 11th largest by enrollment of the 11 interventional ones that give a count, is one of 3 that started in 2004, is one of 6 in phase 4, and was the 5th registered.

Herpes Genitalis

70 studies on the registry are indexed under Herpes Genitalis; 3 are open to participants now.

Browse Herpes Genitalis studies →

Open to participants now

None of the 14 studies testing valacyclovir in Herpes Genitalis is open now. The open studies under Herpes Genitalis, anywhere →

About valacyclovir

Valacyclovir: first FDA approval 1995 (VALTREX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1 Herpes Genitalis study recruiting now, none set no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies testing valacyclovir in Herpes Genitalis as a file.
02

Study summary

This clinical research study will be an international trial evaluating the safety and effectiveness of a marketed drug compared to placebo (like a sugar pill) for the suppression of repeated genital herpes infections in HIV-infected subjects with CD4+ count \<100 cells/mm3.

03

Conditions studied

  • Herpes Genitalis

Keywords

  • Herpes
  • Genital Herpes
  • HIV
  • HSV
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • \<100cells/mm3 at the screening visit.
  • Documented history of infections
  • Must have received stable, combination anti HIV drugs for at least 4 months immediately prior to participation, and per the investigator, are unlikely to require change in anti-HIV drugs during the six-month study.
  • Laboratory confirmation of genital herpes (a positive Herpes Simplex Virus-2 antibody test).
  • 3 or more outbreaks of genital herpes in the previous 12 months if not on genital herpes medicines currently.
  • 3 or more outbreaks of genital herpes per year in the period prior to beginning of treatment for chronic genital herpes.

Exclusion criteria

Exclusion Criteria:

  • Kidney diseases.
  • Liver diseases.
  • Known allergic reactions to VALTREX (valaciclovir), ZOVIRAX (acyclovir), FAMVIR (famciclovir), or CYTOVENE (ganciclovir).
  • Vomiting syndrome.
  • Must be willing to discontinue taking current genital herpes medicines 1 week prior to participation.
  • Active AIDS-indicator conditions, as defined by CDC Category C.
  • Other protocol inclusion and exclusion criteria to be evaluated by the research physician.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Suppressive + Episodic Therapy

    Valaciclovir (VAL) 500mg twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 days or 10 days, when required for treatment of a genital herpes recurrence.

    Drug: valacyclovir hydrochloride

  • Placebo comparator
    Episodic Therapy

    Matching placebo twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 or 10 days, when required for treatment of a genital herpes recurrence.

    Drug: valacyclovir hydrochloride

Interventions

06

What researchers measure

Primary outcomes

  1. Adverse Events

    The nature and incidence of adverse events, by treatment group, reported during the 6-month study will be summarized.

    Time frame: Up to 6 months

Secondary outcomes

  1. Proportion of recurrence of genital HSV

    Secondary outcome measures are the proportion of subjects recurrence-free of genital HSV at 6 months, and the time to first culture-positive recurrence of genital HSV.

    Time frame: Up to 6 months

  2. Time to first culture-positive recurrence of genital HSV

    Secondary outcome measures are the proportion of subjects recurrence-free of genital HSV at 6 months, and the time to first culture-positive recurrence of genital HSV.

    Time frame: Up to 6 months

07

Study locations

5 sites
  • GSK Investigational Site
    Altamonte Springs, Florida 32701, United States
  • GSK Investigational Site
    Chicago, Illinois 60657, United States
  • GSK Investigational Site
    Boston, Massachusetts 02115, United States
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Kowloon Bay, Hong Kong
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2004 to primary completion in Oct 2004, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2004
First posted
Mar 19, 2004
StartActual
Mar 12, 2004
Primary completionActual
Oct 15, 2004
CompletionActual
Oct 15, 2004
Last update
Nov 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00079911
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Mar 19, 2004
Start date
Mar 12, 2004
Primary completion
Oct 15, 2004
Completion
Oct 15, 2004
Last update
Nov 24, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valacyclovir

Start the discussion